Clinical trial

Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC

NCT05203276

Study summary

ClinicalTrials.gov

Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Envafolimab Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Endostar Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2022-03-01

PhasePHASE2

Conditions

Lung Neoplasmsverified · MONDO: lung neoplasm

Interventions

EnvafolimabDRUG

EndostarDRUG

Sponsors & collaborators

The First People's Hospital of Lianyunganglead sponsor

Mapped research locations

LianyungangJiangsu, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05203276 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.